Zolmytryptan

When ATH:
N02CC03

Characteristic.

White or almost white powder. Easily soluble in water. Molecular weight 287,36.

Pharmacological action.
Protivomigrenoznoe.

Application.

Migraine (kupirovanie access).

Contraindications.

Hypersensitivity, severe hypertension, CHD, WPW-syndrome with arrhythmias, severe liver, children and old (after 65 years) age.

Pregnancy and breast-feeding.

Maybe, if the effect of therapy outweighs the potential risk to the fetus.

Category actions result in FDA - C. (The study of reproduction in animals has revealed adverse effects on the fetus, and adequate and well-controlled studies in pregnant women have not held, However, the potential benefits, associated with drugs in pregnant, may justify its use, in spite of the possible risk.)

At the time of treatment should stop breastfeeding.

Side effects.

Nausea, dry mouth, dizziness, drowsiness, feeling the heat, asthenia, a feeling of heaviness and constriction in the throat, neck, limbs and chest, transient increase in blood pressure, myalgia, muscular weakness, paraesthesia.

Cooperation.

Moclobemide increases the content in tissues. Acceptable combination with other agents protivomigrenoznymi (ergotamin, digidroergotamin, paracetamol and others.).

Overdose.

Symptoms: sedation.

Treatment: simptomaticheskaya therapy, incl. airway, monitoring and maintaining the function of the cardiovascular system.

Dosing and Administration.

Inside, 2,5 mg. При отсутствии эффекта или рецидивировании боли повторно через 2 no. Максимальная однократная доза — 5 mg, The maximum daily dose - 15 mg.

Precautions.

Before the start of treatment should be detailed neurological examination to exclude organic pathology of CNS, as well as the assessment of the cardiovascular system. Not recommended intake along with others. drugs from the group of 5-HT agonists_1D receptors and the use for the prevention of migraine. Should not be used during the drivers of vehicles and people, skills relate to the high concentration of attention.